Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trials. The company has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC, GlaxoSmithKline, and Zentera Therapeutics (Cayman), Ltd.
Market Cap | 0 | Shares Outstanding | 0 | Avg 30-day Volume | 627.526 Thousand |
P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -2.58 |
Price to Revenue | 0.0 | Debt to Equity | 0.0 | EBITDA | -221.772 Million |
Price to Book Value | 6.6209 | Operating Margin | 0.0 | Enterprise Value | 1.763 Billion |
Current Ratio | 6.928 | EPS Growth | -12.485 | Quick Ratio | 6.655 |
1 Yr BETA | 1.8109 | 52-week High/Low | 59.65 / 17.33 | Profit Margin | 0.0 |
Operating Cash Flow Growth | -55.2926 | Altman Z-Score | 11.4164 | Free Cash Flow to Firm | -152.905 Million |
Earnings Report | 2023-02-23 |
Please sign in first
none
20 Thousand total shares from 4 transactions
none
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
GALLAGHER CAM PRESIDENT |
|
352,011 | 2023-01-17 | 14 |
EPPERLY MELISSA B, CHIEF FINANCIAL OFFICER |
|
297,543 | 2022-10-03 | 4 |
BUNKER KEVIN D. CHIEF SCIENTIFIC OFFICER |
|
959,460 | 2022-10-03 | 10 |
BROWNSTEIN CARRIE CHIEF MEDICAL OFFICER |
|
0 | 2022-10-03 | 2 |
|
36,606 | 2022-09-09 | 2 | |
PAUL ANDREA GENERAL COUNSEL |
|
0 | 2022-08-01 | 2 |
|
108,330 | 2022-06-08 | 1 | |
|
21,817 | 2022-06-08 | 1 | |
|
9,199,973 | 2022-05-18 | 1 | |
BLACKWELL KIMBERLY PRESIDENT & CEO |
|
2,136,011 | 2022-05-16 | 1 |
SUN ANTHONY Y PRESIDENT & CEO |
|
2,592,141 | 2022-04-04 | 4 |
VOLIOTIS DIMITRIS SVP, CLINICAL DEVELOPMENT |
|
56,791 | 2022-02-10 | 1 |
PINTO ALEXIS CHIEF LEGAL OFFICER |
|
83,660 | 2022-02-10 | 1 |
VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC |
|
No longer subject to file | 2020-12-01 | 0 |
|
No longer subject to file | 2020-10-28 | 0 | |
|
0 | 2020-04-03 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2023-01-18 17:15:03 -0500 | 2023-01-17 | S | 9,500 | $24.11 | d | 352,511 | direct | yes | 2.5032 | -0.8632 | 2.5032 | 2 | -0.8632 | 6 | ||
2023-01-18 17:15:03 -0500 | 2023-01-17 | S | 500 | $24.87 | d | 352,011 | direct | yes | 2.5032 | -0.8632 | 2.5032 | 2 | -0.8632 | 6 | ||
2023-01-05 19:16:31 -0500 | 2023-01-05 | S | 9,700 | $21.01 | d | 362,311 | direct | yes | -12.6355 | 17.586 | 17.586 | 6 | -12.6355 | 2 | ||
2023-01-05 19:16:31 -0500 | 2023-01-05 | S | 300 | $21.46 | d | 362,011 | direct | yes | -12.6355 | 17.586 | 17.586 | 6 | -12.6355 | 2 |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|---|---|---|---|
ZENTALIS PHARMACEUTICALS INC ZNTL | 2023-01-27 22:15:03 UTC | 3.5549 | 0.7651 | 400000 |
ZENTALIS PHARMACEUTICALS INC ZNTL | 2023-01-27 21:45:04 UTC | 3.5549 | 0.7651 | 400000 |
ZENTALIS PHARMACEUTICALS INC ZNTL | 2023-01-27 21:15:04 UTC | 3.5549 | 0.7651 | 400000 |
ZENTALIS PHARMACEUTICALS INC ZNTL | 2023-01-27 20:45:03 UTC | 3.5549 | 0.7651 | 400000 |
ZENTALIS PHARMACEUTICALS INC ZNTL | 2023-01-27 20:15:04 UTC | 3.5549 | 0.7651 | 400000 |
ZENTALIS PHARMACEUTICALS INC ZNTL | 2023-01-27 19:45:03 UTC | 3.5549 | 0.7651 | 400000 |
ZENTALIS PHARMACEUTICALS INC ZNTL | 2023-01-27 19:15:03 UTC | 3.5549 | 0.7651 | 400000 |
ZENTALIS PHARMACEUTICALS INC ZNTL | 2023-01-27 18:45:04 UTC | 3.5549 | 0.7651 | 400000 |
ZENTALIS PHARMACEUTICALS INC ZNTL | 2023-01-27 18:15:03 UTC | 3.5549 | 0.7651 | 400000 |
ZENTALIS PHARMACEUTICALS INC ZNTL | 2023-01-27 17:45:03 UTC | 3.5549 | 0.7651 | 400000 |
ZENTALIS PHARMACEUTICALS INC ZNTL | 2023-01-27 17:15:04 UTC | 3.5549 | 0.7651 | 400000 |
ZENTALIS PHARMACEUTICALS INC ZNTL | 2023-01-27 16:45:03 UTC | 3.5743 | 0.7457 | 400000 |
ZENTALIS PHARMACEUTICALS INC ZNTL | 2023-01-27 16:15:03 UTC | 3.5743 | 0.7457 | 400000 |
ZENTALIS PHARMACEUTICALS INC ZNTL | 2023-01-27 15:45:03 UTC | 3.5743 | 0.7457 | 400000 |
ZENTALIS PHARMACEUTICALS INC ZNTL | 2023-01-27 15:15:04 UTC | 3.5743 | 0.7457 | 400000 |
ZENTALIS PHARMACEUTICALS INC ZNTL | 2023-01-27 14:45:04 UTC | 3.5743 | 0.7457 | 400000 |
ZENTALIS PHARMACEUTICALS INC ZNTL | 2023-01-27 14:15:03 UTC | 3.5743 | 0.7457 | 400000 |
ZENTALIS PHARMACEUTICALS INC ZNTL | 2023-01-27 13:45:03 UTC | 3.8902 | 0.4298 | 400000 |
ZENTALIS PHARMACEUTICALS INC ZNTL | 2023-01-27 13:15:03 UTC | 3.8902 | 0.4298 | 400000 |
ZENTALIS PHARMACEUTICALS INC ZNTL | 2023-01-27 12:45:03 UTC | 3.8902 | 0.4298 | 400000 |
Holder | Issuer | Net Short Position | Position Date | Origin |
---|---|---|---|---|
Trust for Professional Managers- Convergence Long/Short Equity Fund | ZNTL | -344.0 shares, $-28225.2 | 2021-11-30 | N-PORT |
Weiss Strategic Interval Fund- Weiss Strategic Interval Fund | ZNTL | -2903.0 shares, $-62878.98 | 2022-09-30 | N-PORT |